Västmanlands sjukhus Västerås
Welcome,         Profile    Billing    Logout  
 19 Trials 
45 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Ji-Youn
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NCT01470716: Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Active, not recruiting
2
26
RoW
Erlotinib, treatment arm
National Cancer Center, Korea, Hoffmann-La Roche
NSCLC Stage II, NSCLC, Stage IIIA
12/21
06/22
AvaTa, NCT03126799: A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Active, not recruiting
2
128
RoW
Erlotinib plus Bevacizumab, Tarceva plus Avastin, Erlotinib, Tarceva
National Cancer Center, Korea, Roche Korea co.,Ltd.
EGFR Positive Non-small Cell Lung Cancer
12/21
07/23
NCT03808480: Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

Recruiting
2
22
RoW
CA and Nivolumab, Opdivo
National Cancer Center, Korea
Non-small Cell Lung Cancer
05/22
05/22
NCT01441349: Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

Active, not recruiting
2
192
RoW
IP chemotherapy, IP, IP chemotherapy plus simvastatin, IPSimva
National Cancer Center, Korea
Small Cell Lung Carcinoma
10/22
12/22
NCC-2018-0232, NCT03612154: Study of Lorlatinib in ROS1 Rearranged NSCLC

Recruiting
2
35
RoW
Lorlatinib
National Cancer Center, Korea
Nonsmall Cell Lung Cancer
12/22
12/23
NCT03262454: Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

Recruiting
2
35
RoW
Atezolizumab, Tecentriq
National Cancer Center, Korea, Roche Korea co.,Ltd.
Small Cell Lung Cancer Recurrent
02/23
07/24
NCT04074993: Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Active, not recruiting
2
35
RoW
Brigatinib
JI-YOUN HAN, Seoul National University Hospital, Severance Hospital, Seoul National University Bundang Hospital
Non Small Cell Lung Cancer
01/25
03/25
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting
2
40
US, RoW
ABN401
Abion Inc
Advanced Solid Tumors
04/25
08/25
STEREO, NCT04908956 / 2020-004114-35: Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC

Terminated
2
6
Europe, RoW
Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT)
ETOP IBCSG Partners Foundation, AstraZeneca
NSCLC Stage IV, EGFR Gene Mutation
10/23
02/24
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT04052971: To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Completed
1
24
RoW
ABN401- Escalation Phase, ABN401- Expansion Phase
Abion Inc, Novotech (Australia) Pty Limited
Advanced Solid Tumors
11/23
01/24
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
Smedh, Kenneth
NEAPE, NCT01347697: Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer

Active, not recruiting
N/A
91
Europe
Reconstruction with an acellular porcine dermal collagen implant (biological mesh), Reconstruction with a gluteus maximus myocutaneous flap
Umeå University, The Swedish Society of Medicine, Västerbotten County Council, Sweden
Rectal Cancer, Defect of Floor of Lesser Pelvis
09/23
09/24
Segelmark, MÃ¥rten
GOOD-IDES-02, NCT05679401: A Study With Imlifidase in Anti-GBM Disease

Active, not recruiting
3
50
Europe, US, RoW
Imlifidase, IdeS, HMED-IdeS, Plasma exchange (PLEX), PE, Cyclophosphamide (CYC), Glucocorticoids
Hansa Biopharma AB
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
06/25
11/26
SACK, NCT05679024: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Recruiting
3
1400
Europe, RoW
Apixaban 2.5 milligram Oral Tablet
Region Stockholm, Uppsala University
Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular Complication, Death, Kidney Transplant; Complications, Thromboses, Venous
12/27
12/28
Alexander, Jorge A Alatorre
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Park, Sun Yong
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT06348446: Tacrolimus Exposure in Kidney Transplantation

Recruiting
N/A
12000
RoW
Seoul National University Hospital, Astellas Pharma Inc
Kidney Transplant Rejection
07/24
08/24
NCT05597683: Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy

Recruiting
N/A
50
RoW
Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
Gangnam Severance Hospital
Cytoreductive Surgery, Hyperthermic Intra-peritoneal Chemotherapy, Peritoneal Cancer
12/24
01/25
NCT05716672: Impact of Lazertinib Dose Modification on Effectiveness and Safety

Not yet recruiting
N/A
200
RoW
Lazertinib, LECLAZA
Pusan National University Hospital, Yuhan Corporation
Non-small Cell Lung Cancer
12/25
12/25
NCT05804786: Prospective Cohort of Diagnostic Bronchoscopy for Peripheral Lung Lesions

Recruiting
N/A
1240
RoW
Guided bronchoscopy, Device: Spin Thoracic Navigation System, Device: Radial EBUS probe
Seoul National University Bundang Hospital
Lung Cancer
07/27
07/27
Lönnberg, Ingmar
SPIRRIT, NCT02901184 / 2016-002019-16: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

Recruiting
3
2000
Europe, US
Spironolactone, Standard care
Uppsala University, Karolinska University, Duke Clinical Research Institute, National Heart, Lung, and Blood Institute (NHLBI)
Heart Failure With Preserved Ejection Fraction
12/26
12/26
Smedh, Keneth
NEAPE, NCT01347697: Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer

Active, not recruiting
N/A
91
Europe
Reconstruction with an acellular porcine dermal collagen implant (biological mesh), Reconstruction with a gluteus maximus myocutaneous flap
Umeå University, The Swedish Society of Medicine, Västerbotten County Council, Sweden
Rectal Cancer, Defect of Floor of Lesser Pelvis
09/23
09/24
Ranhem, Andreas
NCT03639922 / 2017-000075-85: Imatinib in Acute Ischaemic Stroke

Recruiting
3
1260
Europe
Imatinib 400mg, Placebo Oral Tablet
Niaz Ahmed
Acute Ischaemic Stroke
12/22
06/23
Trujillo, Jose Luis Gonzalez
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Mörth, Charlott
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Rigas, Nikolaos
SACK, NCT05679024: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Recruiting
3
1400
Europe, RoW
Apixaban 2.5 milligram Oral Tablet
Region Stockholm, Uppsala University
Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular Complication, Death, Kidney Transplant; Complications, Thromboses, Venous
12/27
12/28
Thyro-CPR, NCT04392258: Observational and Diagnostical Study on Transient Allostatic Responses of Thyroid Function After Cardiopulmonary Resuscitation

Recruiting
N/A
200
Europe
TSH determination, serum thyrotropin determination, FT4 determination, serum free T4 determination, FT3 determination, serum free T3 determination, SPINA-GT, GT, Thyroid's secretory capacity, LOINC 82368-2, thyroid's incretory capacity, SPINA-GD, GD, Sum activity of peripheral deiodinases, LOINC 82367-4, deiodination capacity
Ruhr University of Bochum
Heart Arrest, Ventricular Fibrillation, Ventricular Flutter, Ventricular Tachycardia
06/22
12/22
Maciel, Manuel Ernesto Magallanes
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Flesche, Jan
SACK, NCT05679024: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Recruiting
3
1400
Europe, RoW
Apixaban 2.5 milligram Oral Tablet
Region Stockholm, Uppsala University
Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular Complication, Death, Kidney Transplant; Complications, Thromboses, Venous
12/27
12/28
Mörtberg, Josefin
SACK, NCT05679024: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Recruiting
3
1400
Europe, RoW
Apixaban 2.5 milligram Oral Tablet
Region Stockholm, Uppsala University
Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular Complication, Death, Kidney Transplant; Complications, Thromboses, Venous
12/27
12/28
Cervantes, Denisse Eugenia Lee
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Murillo, Emilio
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Sahlander, Anna
SACK, NCT05679024: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Recruiting
3
1400
Europe, RoW
Apixaban 2.5 milligram Oral Tablet
Region Stockholm, Uppsala University
Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular Complication, Death, Kidney Transplant; Complications, Thromboses, Venous
12/27
12/28

Download Options